Collection of blood and tissue samples from patients with upper aerodigestive cancers
Immunobiology Blood and Tissue Collection of Upper Aerodigestive Malignancies
This study is collecting blood and tissue samples from patients with certain cancers to see how their treatments affect the immune system and to help improve future cancer therapies.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1250 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Academic / other |
| Drugs / interventions | immunotherapy, radiation |
| Locations | 1 site (Baltimore, Maryland) |
| Trial ID | NCT05995821 on ClinicalTrials.gov |
What this trial studies
This observational study aims to collect and store biological specimens from patients with head and neck, lung, and gastrointestinal cancers who are undergoing treatments that may affect the immune system. The research focuses on understanding how different cancer therapies influence immune responses, identifying risk factors for side effects from immunotherapy, and characterizing molecular features related to treatment response. Participants will provide samples such as blood, tumor tissue, and other biological materials to facilitate these investigations. The ultimate goal is to enhance the design of new therapies and predictive tests for cancer treatments.
Who should consider this trial
Good fit: Ideal candidates include individuals with confirmed or suspected upper aerodigestive malignancies who may be receiving immunomodulating treatments.
Not a fit: Patients with significant contraindications for blood collection or biopsy procedures may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved cancer therapies and better prediction of treatment responses for patients.
How similar studies have performed: Other studies have shown promise in understanding the immunobiology of cancer treatments, making this approach both relevant and potentially impactful.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subjects with a pathologically confirmed or clinically suspected upper aerodigestive malignancy who may be candidates for known or potentially immunomodulating treatments * Ability to understand and willingness to sign a written informed consent document Exclusion Criteria: * Patients with known significant contraindications for venipuncture (e.g., hemoglobin \<8.5 g/dL) will be excluded from the blood collection component of the study * Patients with known significant contraindications for biopsy (e.g., severe bleeding diathesis) will be excluded from the tissue biopsy component of the study * Patients with known significant contraindications for bronchoscopy (e.g., airway concerns, significant cardiac disease) will be excluded from the bronchoscopy component of the study * Unable or unwilling to read English and complete forms/questionnaires
Where this trial is running
Baltimore, Maryland
- Johns Hopkins University — Baltimore, Maryland, United States (Recruiting)
Study contacts
- Principal investigator: Valsamo Anagnostou, MD, PhD — Johns Hopkins University
- Study coordinator: Valsamo Anagnostou, MD, PhD
- Email: ThoracicCancerTrials@jhmi.edu
- Phone: 410-614-8948
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.